ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 357

Predictive Value Of Anti Cyclic Citrullinated Peptide and Rheumatoid Factor To The Development Of Rheumatoid Arthritis In a Cohort Of Healthy Relatives Of Patients With Rheumatoid Arthritis

Jose Dionisio Castillo-Ortiz1 and Cesar Ramos-Remus2, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 2Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Consanguineous relatives of patients with RA are at a higher risk to develop RA. It is also known that specific antibodies including CCP and RF may occur years prior to the disease onset. To assess the predictive value of serum IgM-RF and anti-CCP to the development of RA in a 5-year prospective cohort of healthy consanguineous relatives of RA patients.

Methods: RA patients (ACR criteria) attending one tertiary- and two secondary-care outpatient rheumatology clinics were asked to invite their consanguineous relatives to participate in the study. All patients and relatives underwent medical history; serum IgM-RF (nephelometry) and anti-CCP antibodies (ELISA II) were determined in patients and healthy relatives at baseline. Thereafter participant relatives were contacted by phone every four months using a structured interview (COPCORD questionnaire). When COPCORD was positive subjects had an in-office rheumatology assessment including physical examination, erythrocyte sedimentation rate, and plain x-Ray. The outcome was defined as fulfillment of ACR-EULAR criteria of RA. The Kaplan Meier curve was done to assess the time to the outcome and Cox analysis was used to determine baseline predictors (age, sex, anti-CCP, IgM-RF).

Results: A total of 771 consanguineous relatives from 257 RA patients were included. At baseline, all had COPCORD negative and the mean age was 35 (±12), 69% were females and 33% siblings. Thirteen (2%) subjects were positive to both CCP and RF: 9 (1 %) only to CCP and 16 (2 %) only to RF. Sixteen of 771 subjects (2%) developed rheumatoid arthritis during the 5-yrs follow up (3348 person-years), with an annual rate of 0.5% (Kaplan-Meier). The positive predictive value when CCP and RF are positive was 54% and 56% when only CCP was positive. RF per se had no predictive value (table 1). Cox analysis showed that age at baseline, CCP, RF, and siblings were significant predictors for developing RA over follow-up.

Conclusion: The positivity of CCP may be useful to detect preclinical disease in healthy relatives of RA patients.


Disclosure:

J. D. Castillo-Ortiz,
None;

C. Ramos-Remus,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-value-of-anti-cyclic-citrullinated-peptide-and-rheumatoid-factor-to-the-development-of-rheumatoid-arthritis-in-a-cohort-of-healthy-relatives-of-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology